MMMichael G. Mohsen

Michael G. Mohsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael G. Mohsen has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The GndA Microprotein Promotes Cell Growth during Heat Shock in Escherichia coli

    by Jessica J. Mohsen, Natalia R. Bertolotti, Kevin Jiang, Michael G. Mohsen, Christine M. DeRosa, Nikita Dewani, Laura Quinto, Georgina Dabdoub, Betel Erkalo, Ane Landajuela, et al.

    Hundreds of bacterial small open reading frames (sORFs) encoding microproteins of fewer than 50 amino acids have recently been identified. Biological functions have been ascribed to an increasing number of microproteins, some of which play roles in bacterial stress responses. In this work, we provide evidence that GndA, a frameshifted 36-amino acid microprotein encoded in an internal open reading frame overlapping the 6-phosphogluconate dehydrogenase (6PGD) coding sequence (CDS), functions in the response to heat shock. We demonstrate independent contributions of GndA and 6PGD to cell growth at a high temperature. GndA is hydrophobic and associates with the pyruvate dehydrogenase complex and the inner membrane. Consistent with a role in cellular homeostasis, GndA mutations alter the transcriptional response to heat shock. These results demonstrate that GndA promotes bacterial cell growth at high temperatures independently of the 6PGD protein that it overlaps. GndA thus expands the paradigm of bacterial microproteins that function in cellular stress responses.

  • Open Access

    Author Correction: Guanidine aptamers are present in vertebrate RNAs associated with calcium signaling and neuromuscular function

    by Kumari Kavita, Aya Narunsky, Jessica J. Mohsen, Isha Mahadeshwar, Michael G. Mohsen, Yu-Shin Chang, Ronald R. Breaker


  • Open Access

    Guanidine aptamers are present in vertebrate RNAs associated with calcium signaling and neuromuscular function

    by Kumari Kavita, Aya Narunsky, Jessica J. Mohsen, Isha Mahadeshwar, Michael G. Mohsen, Yu-Shin Chang, Ronald R. Breaker

    Guanidine is a protein denaturant that is a widely used constituent in explosives, plastics, and resins. Its effects on muscle contraction were initially reported in 1876, which eventually led to the use of guanidine as a treatment for certain ataxia symptoms such as those caused by Lambert-Eaton disease. However, its mechanisms of therapeutic action remained unknown. Guanidine was recently found to be a widespread natural metabolite through the discovery of four bacterial riboswitch classes that selectively recognize this compound. Here, we report the discovery and biochemical validation of vertebrate members of guanidine-I and -II riboswitch aptamer classes that are associated with numerous genes relevant to neuromuscular function, mostly involved in Ca2+ transport or signaling. These findings suggest that guanidine is a widely used signaling molecule that serves as an additional layer of regulation of genes relevant to neuromuscular disorders.


  • Open Access

    Engineered Branaplam Aptamers Exploit Structural Elements from Natural Riboswitches

    by Michael G. Mohsen, Matthew K. Midy, Aparaajita Balaji, Ronald R. Breaker

    Drug candidates that fail in clinical trials for efficacy reasons might still have favorable safety and bioavailability characteristics that could be exploited. A failed drug candidate could be repurposed if a receptor, such as an aptamer, were created that binds the compound with high specificity. Branaplam is a small molecule that was previously in development to treat spinal muscular atrophy and Huntington's disease. Here, we report the development of a small (48-nucleotide) RNA aptamer for branaplam with a dissociation constant of similar to 150 nM. Starting with a combinatorial RNA pool integrating the secondary and tertiary structural scaffold of a Guanine-I riboswitch aptamer interspersed with regions of random sequence, in vitro selection yielded aptamer candidates for branaplam. Reselection and rational design were employed to improve binding of a representative branaplam aptamer candidate. A resulting variant retains the pseudoknot and two of the paired elements (P2 and P3) from the scaffold but lacks the enclosing paired element (P1) that is essential for the function of the natural Guanine-I riboswitch aptamer. A second combinatorial RNA pool based on the scaffold for TPP (thiamin pyrophosphate) riboswitches also yielded a candidate offering additional opportunities for branaplam aptamer development.


  • Pervasive transcriptome interactions of protein-targeted drugs

    by Linglan Fang, Willem A. Velema, Yujeong Lee, Lu Xiao, Michael G. Mohsen, Anna M. Kietrys, Eric T. Kool

    The off-target toxicity of drugs targeted to proteins imparts substantial health and economic costs. Proteome interaction studies can reveal off-target effects with unintended proteins; however, little attention has been paid to intracellular RNAs as potential off-targets that may contribute to toxicity. To begin to assess this, we developed a reactivity-based RNA profiling methodology and applied it to uncover transcriptome interactions of a set of Food and Drug Administration-approved small-molecule drugs in vivo. We show that these protein-targeted drugs pervasively interact with the human transcriptome and can exert unintended biological effects on RNA functions. In addition, we show that many off-target interactions occur at RNA loci associated with protein binding and structural changes, allowing us to generate hypotheses to infer the biological consequences of RNA off-target binding. The results suggest that rigorous characterization of drugs’ transcriptome interactions may help assess target specificity and potentially avoid toxicity and clinical failures.


  • Open Access

    Exploiting natural riboswitches for aptamer engineering and validation

    by Michael G Mohsen, Matthew K Midy, Aparaajita Balaji, Ronald R Breaker

    Over the past three decades, researchers have found that some engineered aptamers can be made to work well in test tubes but that these same aptamers might fail to function in cells. To help address this problem, we developed the ‘Graftamer’ approach, an experimental platform that exploits the architecture of a natural riboswitch to enhance in vitro aptamer selection and accelerate in vivo testing. Starting with combinatorial RNA pools that contain structural features of a guanine riboswitch aptamer interspersed with regions of random sequence, we performed multiplexed in vitro selection with a collection of small molecules. This effort yielded aptamers for quinine, guanine, and caffeine that appear to maintain structural features of the natural guanine riboswitch aptamer. Quinine and caffeine aptamers were each grafted onto a natural guanine riboswitch expression platform and reporter gene expression was monitored to determine that these aptamers function in cells. Additionally, we determined the secondary structure features and survival mechanism of a class of RNA sequences that evade the intended selection strategy, providing insight into improving this approach for future efforts. These results demonstrate that the Graftamer strategy described herein represents a convenient and straightforward approach to develop aptamers and validate their in vivo function.